The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
- Conditions
- Type 1 Diabetes
- Interventions
- Registration Number
- NCT02584582
- Lead Sponsor
- Hvidovre University Hospital
- Brief Summary
Aim: To investigate the glucagonostatic effect of glucagon-like peptide-1 (GLP-1) independent of the gastric emptying rate.
- Detailed Description
Aim: To investigate the glucagonostatic effects of glucagon-like peptide-1 (GLP-1) during prolonged and intermittent stimulation of the GLP-1 receptor independent of the gastric emptying rate. Glucagon concentrations will be measured following a liquid meal administered in duodenum at baseline and after exenatide, and liraglutide treatment.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10
- Type 1 Diabetes
- >18 years
- No residual beta-cell function (stimulated C-peptide < 60 pmol)
- Pancreatitis
- gastroparesis
- history of alcohol and/or drug abuse
- pregnancy and lactation
- other medical or psychological condition that made the patient unsuitable for study participation according to the investigators´ assessment
- contraindications to gastroscopy
- cancer (unless in complete remission > five years)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Baseline + Liquid meal test Liquid meal test Baseline day with no additional medication Baseline + Liquid meal test No drug (Baseline day) Baseline day with no additional medication Liraglutide + Liquid meal test Liraglutide Liraglutide 1.2 mg once daily for 14 days (0.6 mg/day for one week, escalated to 1.2 mg/day after one week) Liraglutide + Liquid meal test Liquid meal test Liraglutide 1.2 mg once daily for 14 days (0.6 mg/day for one week, escalated to 1.2 mg/day after one week) Exenatide + Liquid meal test Liquid meal test Exenatide 10 mcg twice daily for 14 days (5 mcg twice daily for one week, escalated to 10 mcg twice daily after one week) Exenatide + Liquid meal test Exenatide Exenatide 10 mcg twice daily for 14 days (5 mcg twice daily for one week, escalated to 10 mcg twice daily after one week)
- Primary Outcome Measures
Name Time Method Glucagon concentration (postprandial) 4 hours glucagon area under the curve (AUC) (0-240 minutes) and baseline to peak increments will be calculated
- Secondary Outcome Measures
Name Time Method Oxyntomodulin 4 hours Oxyntomodulin AUC (0-240 minutes) and baseline to peak increments will be calculated
Gastrin 4 hours Gastrin AUC (0-240 minutes) and baseline to peak increments will be calculated
Postprandial glucose concentrations 4 hours glucose AUC (0-240 minutes) and baseline to peak increments will be calculated
glucagon-like peptide-1 (GLP-1) 4 hours GLP-1 AUC (0-240 minutes) and baseline to peak increments will be calculated
glucagon-like peptide-2 (GLP-2) 4 hours GLP-2 AUC (0-240 minutes) and baseline to peak increments will be calculated
glucose-dependent insulinotropic polypeptide (GIP) 4 hours GIP AUC (0-240 minutes) and baseline to peak increments will be calculated
Cholecystokinin (CCK) 4 hours CCKAUC (0-240 minutes) and baseline to peak increments will be calculated
Peptide YY (PYY) 4 hours PYY AUC (0-240 minutes) and baseline to peak increments will be calculated
Ghrelin 4 hours Ghrelin AUC (0-240 minutes) and baseline to peak increments will be calculated
Free fatty acids (FFA) 4 hours FFA AUC (0-240 minutes) and baseline to peak increments will be calculated
triacylglycerol (TAG) 4 hours TAG AUC (0-240 minutes) and baseline to peak increments will be calculated